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“Be nice to nerds. Chances are you’ll end up working for one.” 
      Bill Gates 
 
 
POPULAR SCIENCE SUMMARY OF THE THESIS 
The adrenal glands are hormone-producing organs located above the kidneys. Their function 
is to produce hormones regulating different processes in the body. Possibly, the most 
commonly known hormones of the adrenal glands are adrenaline and noradrenaline, involved 
in regulation of heart rate and blood pressure.  The adrenal glands are further divided into an 
outer layer, which is called the adrenal cortex and a central part called the adrenal medulla. 
Tumors of the adrenal glands are categorized based on which region of the adrenal glands they 
appear in, which will also decide the characteristics, presumed symptoms and treatment.  
From the adrenal cortex, adrenocortical carcinomas (ACCs) originate. These tumors are often 
aggressive with a poor prognosis. Pheochromocytomas (PCCs) originate from the adrenal 
medulla. Additionally, tumors of the, so called, paraganglia (Paragangliomas=PGLs) have a 
similar background as PCCs and are therefore often grouped together and referred to as PPGLs.  
In this thesis different aspects of the background of adrenal tumors are investigated, focusing 
on PPGLs. 
In Paper I, the presence of a protein called NF1 is investigated in PCCs. Mutations, which are 
genetic changes, in the NF1 gene occur in PCC and can potentially cause abnormalities in the 
protein NF1. Information regarding such abnormalities are advantageous for the physician to 
know about, as these changes can cause several other different lesions. The only existing way 
to find out if a genetic change is present is through genetic investigations. The aim of this paper 
was to find out if we could use a simple protein detecting method to achieve the same purpose. 
NF1 protein presence was therefore investigated in a group of tumors containing both NF1 
mutated and not mutated samples. The results showed no specific difference between NF1 
mutated and not mutated cases making this method a less desirable implement to detect NF1 
mutations. Based on these results we conclude that genetic testing is still the best way in the 
search for NF1 mutations.  
In Paper II and III, the underlying mechanisms of PPGLs and ACCs are further investigated. 
In every cell in the body the genome is protected by something called telomeres, which are the 
end parts of each chromosome. The telomeres make sure the cell can only divide a limited 
number of times, thereby protecting the cell from uncontrolled division. However, in several 
tumor types, the telomere elongation complex, telomerase, has been found to be upregulated, 
ensuring unlimited cell replication, an important trait of a tumor cell. In these papers, different 
mechanisms for the tumor cell to activate this elongation is found and linked to worse disease 
and shorter survival.   
In Paper IV, the amount of protein templates expressed by different genes in PPGLs are 
investigated and compared to the characteristics of the tumor. The findings of the investigation 
point out one gene of particular interest, CHGB, as the gene most coupled to aggressive disease. 
The protein encoded by this gene was found to be less expressed in PPGL tumors compared to 
normal adrenals and this difference was also found in blood samples. Our findings suggest that 
analysis of the amount of CHGB in the tissue and in the blood could give a hint about the 
potential aggressiveness of the tumor, giving clinicians a better chance of predicting the clinical 
course of the tumor.  
In Paper V, investigations of the genome resulted in the discovery of a new gene, CACNA1H, 
recurrently altered in PCCs. CACNA1H has previously been found altered in tumors of the 
adrenal cortex and has also been coupled to disease mechanisms, however, it has never 
previously been found altered in PPGLs. Moreover, the expression of this gene and protein was 
found to be downregulated in PCC tumors compared to normal adrenal. These findings suggest 
that CACNA1H might be one piece of the puzzle of the genetic mechanisms behind the 





Adrenal tumors have varying clinical presentation, malignancy rates and patient morbidity. 
Adrenal cortical carcinomas (ACCs) are malignant tumors originating from the adrenal cortex. 
Pheochromocytomas (PCCs) arise from the adrenal medulla and abdominal Paragangliomas 
(PGLs), a highly related tumor type, arise in paraganglia mostly in the abdominal area. The 
genetic background of these tumors has been persistently studied, still knowledge is lacking 
regarding tumor development and genotype-phenotype relation.   
In Paper I, NF1 protein expression was investigated in an attempt to clarify a possible 
association between NF1 mutational status and immunohistochemical staining for NF1. The 
results showed absent NF1 immunoreactivity in most PCCs. A clear majority of the NF1 
mutated cases showed no NF1 immunoreactivity, however that was also seen in the NF1 wild-
type cases. From this study we conclude that immunohistochemistry is not an efficient 
screening tool to detect NF1 mutated cases in clinical practice.  
In Paper II and III, TERT promoter methylation densities were investigated in PPGLs and 
ACCs. Telomerase activation have been shown in these tumor types, however only some cases 
with telomerase activation could be explained by TERT promoter mutations. In PPGLs TERT 
promoter hypermethylation was found in metastatic PGLs. In ACCs hypermethylation of the 
TERT promoter region was found compared to normal adrenal samples and hypermethylation 
was associated with worse clinical outcome. Also, TERT copy number gain was observed in 
ACCs. We concluded that epigenetic alterations of TERT occur in PPGLs and ACCs and are 
associated with worse clinical outcome.  
In Paper IV, histological signs of malignant behavior and mRNA expressional profiles were 
compared in PPGLs. The results pointed out Chromogranin B (CHGB) as the gene most 
significantly associated to malignant histological patterns and downregulation of CHGB was 
found in PPGLs with metastatic disease. Immunohistochemistry showed that weak CHGB 
expression was associated with histologically malignant behavior. Also, plasma levels of 
CHGB were lower in PPGLs with histologically aggressive disease. We concluded that CHGB 
is a possible marker for malignant disease in PPGLs.  
In Paper V, analysis of whole-exome sequencing data from our cohort as well as from the 
TCGA database revealed several variants in the calcium voltage-gated channel subunit gene 
CACNA1H. A total of seven variants were detected in the study. CACNA1H expression was 
found to be lower in tumor tissue as compared to normal adrenal medulla. In the TCGA 
database a correlation was found between CACNA1H methylation levels and CACNA1H 
expression. We concluded that variants in CACNA1H are a possible novel genetic event in 
PPGL and also a possible link between the genetic background of PPGLs and tumors of the 
adrenal cortex where CACNA1H mutations have also been found.  
Overall this thesis gives some clarity to the knowledge gaps in the molecular background of 
tumors of the adrenal glands.    
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 1 
1 LITERATURE REVIEW 
1.1 THE ADRENAL GLANDS 
In the perirenal fat, on top of the kidneys, the adrenal glands are found (Figure 1) (1). The adrenals 
have an important role as they produce and secrete hormones and therefore take part in regulation 
of other organs (2). Around each adrenal is a capsule of connective tissue where nerves and blood 
vessels are connecting to the organ (1).  
The blood supply of the adrenals is divided into the superior suprarenal arteries, the middle 
suprarenal arteries and the inferior suprarenal arteries (Figure 2) (3). The arteries have been 
branched several times before entering the adrenals and the branches are made from the inferior 
phrenic arteries, the abdominal aorta and from the renal arteries (3). The tissue is rich in capillaries 
and sinusoids which enables hormone release into the blood stream (3, 4). 
The adrenal cortex, which originates from the mesodermal mesenchyme, constitutes about 90% 
of the adrenal weight (1). It is in turn separated into three different layers, each with a typical 
hormonal profile. The hormones produced are all steroid hormones subdivided into 
glucocorticoids, mineralocorticoids and sex hormones (2). The outer layer called zona 
glomerulosa secretes mineralocorticoids where aldosterone is the main secretory product (1). 
Aldosterone is a regulator of extracellular volume (2) and therefore also a regulator of the blood 
pressure. The middle layer is called zona fasciculata and composes about 80% of the total cortical 
volume. Most of the secretion of this layer is glucocorticoids where one important hormone is 
Figure 1. The Adrenal glands located in the abdomen above the kidneys. The adrenal 
glands consist of the adrenal cortex and the adrenal medulla, surrounded by a capsule.  
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cortisol (1). Glucocorticoids have many functions. Raising plasma glucose levels, suppressing the 
immune system, anti-inflammatory effects and effector of the calcium and bone metabolism are 
just a few examples of the roles glucocorticoids play in the body (2). Zona fasciculata also secretes 
low amounts of gonadocorticoids (sex hormones) where dehydroepiandrosterone (DHEA) is one 
of the dominant ones (1). This hormone results in a masculine effect but usually only to a small 
extent. The inner layer, and also the smallest part of the cortex, is called Zona reticularis (Figure 
3). This layer of the adrenal cortex secretes mostly gonadocorticoids but also low amounts of 
glucocorticoids (1). 
 
The adrenal medulla consists of chromaffin cells as well as connective tissue, blood capillaries 
and nerves (Figure 3) (1). The chromaffin cells are of a different origin than the parenchymal cells 
in the cortex (1). It was prevously believed that the chrommaffin cells in the adrenal medulla were 
derived from neural crest cells, however, recent studies propose that they might also originate 
from Schwann cell precursors (5). The adrenal medulla secretes catecholamines, mainly 
adrenaline and noradrenaline where adrenaline dominates the secretion profile (1). As presynaptic 
sympathetic nerves are directly connected to the chromaffin cells inside the medulla, the secretion 
of adrenaline (epinephrine) and noradrenaline (norepinephrine)  is carried out directly when a 
Figure 2. The arteries surrounding the adrenal glands. The illustration is inspired by Fig 
15.16, page 217 in Gilroy et al. (4)  
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nerve impulse is sent out to the area (1). Also, from the medullary cells, chromogranin A (CHGA), 
a protein present in the adrenal medullary cells, is released together with the catecholamines and 
is used as an indicator of activity of the medullary part of the organ (2). 
 
1.2 THE DEVELOPMENT OF TUMORS 
Tumors are developed from ordinary cells that have lost their normal abilities. The origin of a 
tumor can thereby often be found by histopathological methods, as features from the original cell 
often remains in the tumor cell (6). Tumors are divided in two principally different categories 
based on the tendency to invade surrounding tissue and to cause metastases, where the ones that 
do are called malignant and the ones that do not are called benign (6). Malignant tumors often 




Figure 3. Histological image of the adrenal gland in hematoxylin and eosin staining. The 
upper and lower parts showing the adrenal cortex (AC) (Zona reticularis) and the middle 
part showing the adrenal medulla (AM).  
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metastases (6). Benign tumors can, however, still be cause for concern if it applies pressure on 
sensitive organs or give rise to excessive hormone production (6).  
When discussing the development of human tumors, the well-known description “Hallmarks of 
cancer” are often mentioned (7, 8). It summarizes traits acquired by the cell in the multiple step 
processes of tumor and cancer development (7, 8). The hallmarks are described in the following 
section and schematically illustrated in Figure 4. 
Originally six hallmarks were proposed: 
-  Sustaining proliferative signaling is an important and essential characteristic of a tumor cell 
(7). While normal cells of a tissue keep a balance between proliferation and cell death to ensure 
normal function of the tissue, tumor cells have repressed signals that prohibit proliferation and 
thereby divide in an uncontrolled manner (7). 
-  Evading growth suppressors describes the tumors ability to escape the functions of the many 
growth suppressor proteins that operate in the cell, among others p53 (7). 
-  Activating invasion and metastasis describes the cascade of steps required for the tumor to 
expand from the origin and invade nearby tissue and send out distant metastases (7). 
-  Enabling replicative immortality ensures the tumor cell unlimited number of replications, as 
opposed to normal cells that can replicate only a limited number of times (7). A central role is 
thought to be played by telomerase, a DNA polymerase that adds telomere repeats to the 
telomeres securing that the telomere length is retained. While telomerase is not supposed to be 
expressed in most normal cells, telomerase activation is often seen in tumors (7). 
-  Inducing angiogenesis is a way for the tumor to ensure infusion of nutrients and to be able to 
export waste products (7). Angiogenesis in tumors is often active and a necessity to keep up 
growth and proliferation rate (7). 
-  Resisting cell death is another important quality of a tumor cell. The ability of apoptosis, where 
the cell itself induces cell death as a result of stress or unfavorable conditions in the cell, is lost 
in tumor cells. This reduces self-controlled cell death (7). 
Two additional hallmarks were added after considerable amount of research proposed their 
importance (7).  
-  Deregulating cellular energetics will help the cell reprogram energy sources to acquire 
unceasing proliferation and cell growth (7). 
- Avoiding immune destruction point out the tumor cell’s ability to avoid being occupied and 
eliminated by the immune system (7). 
Beside the six original and the two later added hallmarks of cancer, two enabling characteristics 
have been proposed in a way of further distinguish favorable conditions (7).  
 
 5 
-   Genome instability and mutation relate to the condition of which a higher number of casual 
mutations are made possible as well as chromosomal rearrangement (7). This can lead to 
approved conditions for further hallmark development (7). 
-   Tumor-promoting inflammation describes the ability of the neoplasm to utilize the immune 
response to create a favorable environment for tumor growth, for example providing growth- 
and proliferation promoting molecules to the microenvironment (7).  
 
1.3 GENETIC AND EPIGENETIC TUMOR BIOLOGY 
Looking at the genetic background in tumor biology, there are two different types of genes 
typically involved in tumor development, oncogenes and tumor-suppressor genes (9). Oncogenes 
are genes whose protein product have the potential to cause tumors (9, 10). Most of these 
oncogenes have their origin in normal genes (then called proto-oncogenes) known to play a part 
Figure 4. The hallmarks of cancer. The illustration is inspired by Figure 1, 3 and 6 in 
Hanahan et al. (7). 
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in cell growth control (9). Typically, the conversion of a proto-oncogene to an oncogene is a 
consequence of a gain-of-function mutation, such as a missense mutation, translocation or 
amplification (9). Tumor suppressor genes, however, are genes whose protein product suppress 
cell proliferation  (9). Loss-of-function mutations that lead to the loss of functional protein is the 
typical cause when tumor suppressor genes are involved in tumor development (9). 
Tumors can be seen as a result of changes in tumor suppressor genes, proto-oncogenes and genes 
hosting microRNA (11). Most commonly this is caused by a somatic alteration, however, 
germline mutations occur and can give the patient a genetic predisposition to develop certain 
types of tumors (11). In the tumor development, there is rarely only one genetic event responsible 
but a series of events, usually including several genetic areas leading up to the tumor formation 
(11). These alterations can be caused by mutations, rearrangements, gene amplification, deletions 
or epigenetic modifications (11). 
Mutations of the DNA can occur in several different ways with different final effects (Figure 5) 
(12). A silent mutation is a mutation not leading to a change of the amino acid sequence (13). A 
missense mutation is a point mutation resulting in one changed amino acid. Nonsense mutations 
are mutations where a premature stop codon is formed and the amino acid chain shortened (12). 
Additions and withdrawals of one or several nucleotides is called insertions or deletions 
respectively (12). If the number of nucleotides being added or deleted is three or a number 
possible to divide by three, it is called inframe, as the reading frame is not changed. However, if 
Figure 5. Schematic illustration of different types of mutations (left) and the consequence on 
the protein level (right).  
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the reading frame is changed it is called a frameshift, and will then alter the protein from that 
point and forward (12). Two other types of expansions of the DNA are duplication, where a part 
of the DNA is copied one or several times, and repeat expansions where short pieces of DNA is 
repeated numerous times in a row (12). 
1.3.1 Tumor genetics  
The average tumor will harbor a number of somatic mutations and most of these mutations are 
single-base substitutions (14). Most of these substitutions result in missense changes and a 
minority in nonsense changes or changes in splicing. Beyond the single-base substitutions, 
deletions and insertions of bases occur to a lesser extent (14).  
1.3.2 Epigenetics 
The gene expression is controlled by epigenetic mechanisms which are important contributors to 
proper genetic and cellular function. There are different types of epigenetic modifications, all 
defined as heritable non DNA caused changes of genetic expression (15, 16).   
A well-studied epigenetic effect is DNA methylation. Altered methylation patterns are linked to 
different diseases including tumors (15). At the biochemical level the DNA methylation is made 
from addition of a methyl group (-CH3) within a CpG position of the DNA (15). CpG sites are 
often clustered together, referred to as CpG islands, and often located in the promoter region of 
genes (15). Unmethylated DNA usually gives RNA expression while methylated DNA is most 
commonly silent with low expression (15). Altered methylation patterns, including both 
hypomethylation and hypermethylation, can contribute to tumor development (15). 
Hypomethylation can primarily induce cell transformation by causing genetic instability. 
Activation of an oncogene second to hypomethylation is another possible way, however it is less 
common (15). Hypermethylation of the promotor region of a tumor suppressor gene can cause 
silencing of the gene and has been reported for different types of tumors (15).  
 
1.4 TUMORS OF THE ADRENAL CORTEX  
1.4.1 Adrenocortical adenoma (ACA) 
Adenomas of the adrenal cortex (ACA) are found in up to 10% of the population and are frequent 
incidental findings during imaging procedures performed for a different purpose, then referred to 
as incidentalomas (17). They are found in both males and females and are often smaller than five 
cm, however larger adenomas do occur. ACAs can be either nonfunctioning or cause abnormal 
hormone production giving rise to symptoms related to the secreted hormone (17). Primary 
aldosteronism (PA), otherwise known as Conn´s syndrome, is one endocrine consequence due to 
ACA or adrenocortical hyperplasia (17). It is characterized by hyperaldosteronism resulting in 
hypertension (17) and PA has been reported to constitute 5-10% of hypertension (18). Another 
endocrinopathy of ACA is cortisol-producing adenomas giving rise to Cushing’s syndrome, 
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leading to a group of symptoms including hypertension, weight gain and facial rounding, amongst 
others (17).  
1.4.2 Adrenocortical carcinoma (ACC) 
Carcinomas of the adrenal cortex (ACCs) are rare and often highly malignant with a five-year 
survival of 16-38% (19).  The incidence is 0.5-2 per million per year and it is more common in 
females than in males. The median age for disease onset is around 40-59 years, however children 
can also be affected (17). In pediatric cases, the disease is often associated with hereditary 
syndromes of which ACC is a known manifestation (Li-Fraumeni syndrome and Beckwith-
Wiedemann syndrome) (19, 20). About 50% of patients are found due to extensive hormonal 
production. When the tumor is causing elevated hormonal levels, it is called functional and the 
most commonly oversecreted hormone is cortisol (17). Contrary to ACA, the hormone secretion 
may be more clinically discrete as a result of the hormone production sometimes being focused 
to precursor stages of the hormones (19).  
In clinical practice the European Network for the Study of Adrenal Tumors (ENSAT) stage, based 
on tumor size, status of the lymph node and the findings of distant metastases, is used for 
prognostic purposes, where higher ENSAT stage is coupled to worse prognosis (21). After 
thorough clinical evaluation, surgery is suggested for patients without widespread metastatic 
disease (22). There is also one adjuvant treatment approved for ACC, called Mitotane. This 
treatment will result in negative effects on cell growth and steroid production (19), however even 
with this treatment the recurrence rate is high and improved treatment options are needed (23).  
 
1.5 TUMORS OF THE ADRENAL MEDULLA  
1.5.1 Pheochromocytoma (PCC) and Paraganglioma (PGL) 
The tumors of the adrenal medulla are derived from the chromaffin cells and are called 
pheochromocytomas (PCC) (17). The name comes from the Greek language meaning a brown-
black colored mass of cells and refers to the color change of the tumor, due to catecholamine 
oxidation, during pathological investigation and fixation of the tumor cells (24). The first 
complete case was described in Germany 1886 by Felix Fraenkel and his colleague and the same 
year, a pathologist named Max Schottelius, described the histology of PCC for the first time (25). 
Paragangliomas (PGL) are related tumors that arises from the paraganglion cells in the 
sympathetic and parasympathetic paraganglia (17). The sympathoadrenal PGLs are often located 
to the chest, abdomen or pelvic area, following the location of the sympathetic paraganglia (26). 
The parasympathetic PGLs derives from parasympathetic paraganglia located to the upper part 
of mediastinum and to the head and neck region (26). This type of PGL is called “head and neck 
PGL” and in contrast to the PCC and abdominal PGL, it usually does not secrete catecholamines. 
 
 9 
PCCs and abdominal PGLs are thus only parted by their location and somewhat by their genetic 
background. Together, these two tumor types are referred to as PPGLs (26). 
The symptoms of PPGLs are either a consequence of the secretory patterns of the tumors or of 
the growing tumor mass  (27). Commonly, symptoms include extreme hypertension, anxiety, 
sweating, headaches, arrhythmias of the heart and palpitations. The symptoms are often of an 
episodic nature and can be ongoing for hours (27). Since the symptoms often mimic other 
diseases, there is a risk that diagnosis might be misread, and PCC has therefore been nicknamed 
the “great masquerader” (28). 
Malignancy in PPGLs, which is defined as occurrence of metastases, occur in about 10% of PCCs 
and up to 40% of sympathetic PGLs (26) and metastases are often located to the lungs, bones, 
liver and lymph nodes (17). As of recently, the previous classification system of benign and 
malignant PPGLs have been replaced by the notion that all PPGLs have metastatic potential (17), 
thus adding more emphasis on finding efficient screening tools to detect tumors prone to 
metastasize.  
PPGLs occur at an average age of 40-45 years and both genders are affected to approximately the 
same extent (17, 29). Bilateral tumors occur and are more often seen in patients with a genetic 
predisposition while sporadic cases most often have unilateral tumors (29, 30).  
Diagnosis can be based on urinary testing for catecholamine metabolites (27), however plasma 
metanephrines is now the first hand choice because of higher specificity and the fact that it is 
easier to obtain compared to 24-hour urinary sampling (31, 32).  
Surgical removal remains the standard treatment if the tumor is detected in early stages. 
Untreated, the disease is life-threatening, as a consequence of side effects following the symptoms 
(27). After the tumor is removed by surgery the tumor tissue can be investigated for CHGA using 
immunohistochemistry to show neuroendocrine differentiation providing evidence of the 
diagnosis (27). 
1.5.1.1 Histopathological evaluation of PPGLs 
The PCC is usually encapsulated and spongy on the inside. The color is brownish to red and often 
seen with hemorrhage (27). There may also be cystic degeneration (27). Even though the 
histological patterns vary, a typical formation of cells is called zellballen and gives the appearance 
of circular nests (27). Histological images of PCC are shown in Figure 6.  
Behavior related to metastatic properties can sometimes be difficult to recognize histologically 
and therefore aiding scoring systems have been developed. The Pheochromocytoma of the 
Adrenal Gland Scaled Score (PASS) was introduced to distinguish between benign and malignant 
cases (33). PASS includes assessment of the following histological criteria proposed by 
Thompson in 2002 (33); large nests or diffuse growth, central or confluent tumor necrosis, high 
cellularity, cellular monotony, tumor cell spindling, mitotic figures, atypical mitotic figures, 
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extension into adipose tissue, vascular invasion, capsular invasion, profound nuclear 
pleomorphism, and nuclear hyperchromasia (33). The second scoring system is called grading 
system for adrenal pheochromocytoma and paraganglioma (GAPP) (34). The parameters 
included in GAPP are; histological patterns, cellularity status, comedo-type necrosis, capsular or 
vascular invasion, Ki67 status and catecholamine type. These parameters are investigated to 
generate a GAPP score from 0-10 where higher score indicates more poorly differentiated tumor 
(34).    
 
1.6 GENETIC BACKGROUND OF PRIMARY ALDOSTERONISM (PA) 
PA, which is caused by either ACA or by adrenocortical hyperplasia, is the most common cause 
of secondary hypertension (35, 36). Somatic mutations in genes encoding proteins involved in 
ionic homeostasis have been linked to PA. KCNJ5 and CACNA1D are two examples of genes 
associated with PA, resulting in increased calcium levels in the cell (35). Calcium signaling, in 
turn, will give rise to aldosterone production. Also, germline mutations have been reported 
PCC 
Figure 6. Histological image of a PCC in hematoxylin and eosin staining. Upper image is 
showing the PCC towards the capsule. The lower left image is showing the richness in blood 
vessels and the lower right image is showing pleomorphism.  
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coupled to PA, including constitutional mutations of the calcium channel voltage dependent t-
type alpha-1H subunit  (CACNA1H) gene and also infrequently in KCNJ5 (35). In children with 
PA, a recurrent constitutional gain-of-function CACNA1H mutation (M1549V) was found in five 
patients resulting in increased intracellular calcium levels and it was thought to explain the PA 
development in these cases  (37). 
 
1.7 GENETIC BACKGROUND OF ACC 
ACC in adults are mostly sporadic and often associated with somatic mutations of cancer driver 
genes (19), such as TP53 and CTNNB1 (38, 39).  However, there are cancer syndromes, caused 
by mutations in known susceptibility gene, where ACC is a component (19).  
1.7.1 Genetic syndromes predisposing to ACC 
1.7.1.1 Familial adenomatous polyposis  
Familial adenomatous polyposis is an autosomal dominantly inherited disorder where the affected 
patients have an increased risk of developing cancers of different organs, most commonly in the 
colorectal region (20). Also, adrenocortical tumors, both ACA and ACC, have been identified in 
patients with familial adenomatous polyposis. The syndrome is caused by a mutation in the APC 
gene (20, 40, 41), located on chromosomal region 5q22 (www.ensembl.org).  
1.7.1.2 Beckwith-Wiedemann syndrome  
Beckwith-Wiedemann syndrome is a disorder affecting children and resulting in overgrowth and 
tumor development in different organs, including ACCs (20). The syndrome is caused by 
aberrations affecting the insulin-like growth factor 2 gene (IGF2), located in chromosomal region 
11p15, and other genes in the same region (19). 
1.7.1.3 Multiple Endocrine Neoplasia 1 (MEN1) 
Multiple Endocrine Neoplasia 1 (MEN 1) is a disorder linked to tumors of several endocrine 
organs, including the adrenals (42). Patients may develop ACC, however, more commonly MEN 
1 patients present with adrenocortical hyperplasia and also adrenal adenomas in up to 45-55% of 
patients. Hyperplasia and adenomas of the adrenal cortex can secrete hormones or be non-
functional (43). The disorder is caused by a mutation in the multiple endocrine neoplasia type 1 
(MEN1) gene (43). This tumor suppressor gene is located in chromosomal region 11q13 (42). 
1.7.1.4 Lynch syndrome 
Lynch syndrome resulting in cancer of the colon and the endometrium can also result in other 
types of cancers including ACC (19, 44). The syndrome is the result of germline mutations of 
MLH1, MSH2, MSH6, and PMS2. These genes all play a part in DNA mismatch repair (20).    
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1.7.1.5 Li-Fraumeni syndrome 
Li-Fraumeni syndrome is a tumor syndrome caused by a germline TP53 mutation (40). The gene 
is located in chromosomal region 17p13 and works as a tumor suppressor gene by controlling cell 
proliferation (40). ACCs are associated with Li-Fraumeni syndrome and the association is more 
prominent in children, though the ACC penetrance is low (19). 
1.8 GENETIC BACKGROUND OF PPGL 
PPGLs have during the last decade been proven to have a very significant genetic background. 
Genetic testing has shown that 40% of patients have a constitutional mutation in one of several 
susceptibility genes (45, 46). Also, somatic mutations in genes previously linked to different 
cancers have been reported (47). 
1.8.1 Genes associated with heritable susceptibility for PPGL 
Constitutional variants of a variety of different genes have been found in PPGLs and new potential 
susceptibility genes are still being reported. Mutations of most of these genes are considered very 
rare, however, there are a few genes more often found mutated in sequencing studies of PPGLs. 
The most commonly constitutionally mutated gene is VHL (9%), followed by SDHB (6-8%), 
SDHD (5-7%) and RET (5%) (17). 
1.8.1.1 EGLN1 (OMIM 606425) 
EGLN1 is a tumor suppressor gene which encodes the protein PHD2 which is one of the regulators 
of Hypoxia inducible factor alpha (HIFA) (48). The gene is located in chromosomal region 1q42.2 
and mutations have been shown in patients with PPGL disease (48). 
1.8.1.2 EPAS1 (OMIM 603349) 
EPAS1 (aka HIF2A) is an oncogene located in chromosomal region 2p21. The gene encodes the 
endothelial PAS domain-containing protein 1 (aka hypoxia inducible factor 2a) (45), a 
transcription factor involved in cell development (49). Tumor development is enhanced when the 
gene is mutated, leading to inappropriate regulation of the protein, via abnormal activation of 
hypoxia inducible pathways (49). PPGLs can also demonstrate somatic EPAS1 mutation, which 
could also give rise to polycythemia vera and somatostatinoma. A germline mutation can cause 
hereditary polycythemia (45). 
1.8.1.3 FH (OMIM 136850) 
The tumor suppressor gene FH, located in chromosomal region 1q42.1, encodes the protein 
fumarate hydratase (aka fumarase). The protein is active within the tricarboxylic acid cycle 
converting fumarate to malate (45). It has been suggested that a mutation of FH will lead to 
accumulation of fumarate which in turn will lead to a hypermethylator phenotype contributing to 
PPGL development (50). A germline mutation in FH causes Reed syndrome, inherited autosomal 




1.8.1.4 KIF1B (OMIM 605995) 
KIF1B has been suggested as a tumor suppressor gene and has been found mutated in patients 
with PPGL (51). The gene is located in chromosomalregion 1p36 and is thought to enhance 
neuronal apoptosis (51). 
1.8.1.5 MAX (OMIM 154950) 
MAX is a tumor suppressor gene located in chromosomal region 14q23. The gene encodes MYC-
associated protein X (MAX), a protein that works towards downregulating oncogenic signaling 
by transcription factor MYC (45). When mutated it will result in increased cell proliferation (52). 
Mutation of MAX is associated with familial PCC (45).  
1.8.1.6 NF1 (OMIM 613113)  
The NF1 gene encodes neurofibromin, a tumor suppressor protein that works by downregulating 
Ras-protein (45). This will result in an inhibition of the MAPK signaling pathway. The mutated 
form of NF1 will have an abnormal function and thus leading to maintained Ras and inadequate 
activation of MAPK, resulting in cell growth and other tumor promoting mechanisms (53).  The 
gene is found on chromosome 17q11.2, and includes over 50 exons. An inactivating mutation of 
the NF1 gene give rise to Neurofibromatosis type 1 (NF 1), otherwise known as von 
Recklinghausen syndrome, a disorder characterized by different, mostly skin derived, lesions (53, 
54). PCCs in NF 1 are relatively uncommon, however when occurring the tumor is often 
developing at a younger age than sporadic cases of PCC (45).  
1.8.1.7 RET (OMIM 164761) 
The proto-oncogene RET, located in chromosomal region 10q11.2 (45) and encodes a tyrosine 
kinase receptor that, when activated, regulates cell proliferation and apoptosis (53) through 
activation of PI3K-AKT and MAPK-ERK kinase signaling pathways (45).  
Activating mutations of RET cause the syndrome Multiple Endocrine Neoplasia Type 2 (MEN 
2), which is inherited autosomal dominantly (53, 55). Usually, patients present with medullary 
thyroid carcinoma (95%), PCCs (50%) often bilaterally, and primary hyperparathyroidism (15-
30%). Metastatic PCC in this syndrome is rare with an incidence under 5%. Tumor screening of 
MEN 2 patients is often recommended and will sometimes start even during childhood or 
otherwise at 20 years of age. PCCs usually develop between age 30 to 40 years  (53). 
1.8.1.8 SDHx    
The succinate dehydrogenase complex is subject to several mutations that have been linked to 
PPGL (53). This complex, which is equal to the complex II of the mitochondrial respiratory chain, 
consists of several subunits where each one can be host of mutations giving rise to different PGL 
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syndromes (53). Tumors with SDHx-mutations have been found to have a hypermethylator 
phenotype that is thought to negatively regulated genes of importance in neuroendocrine 
differentiation (50). 
SDHD (OMIM 602690) mutations will lead to the paraganglioma syndrome 1 (PGL1). The gene 
is composed of 4 exons and located in chromosomal region 11q23 (53, 56). The encoded protein 
is a small subunit active in the electron transference within the SDHB subunit. PGL1 follows an 
autosomal dominant inheritance pattern, probably more prominent on the paternal side (53). 
The PGL2 syndrome is also an autosomal dominant disorder (53), caused by a mutation in the 
gene SDHAF2 (aka SDH5) (OMIM 613019) which is found in chromosomal region 11q13. The 
gene encodes a protein that is necessary for normal function of the protein SDHA (57).  
A mutation in SDHC (OMIM 602413) will give rise to the PGL3 syndrome, an autosomal 
dominant disease (58). The location of the gene is 1q23.3. The protein is a subunit of the 
cytochrome b within the mitochondrial complex II. This type of SDH mutation is found in 0-6.6% 
of patients with PPGL (53).  
An SDHB (OMIM 185470) mutation will give rise to the PGL4 syndrome (53, 59). The gene, 
found in chromosomal region 1p36, encodes a tumor suppressor which, if mutated, will result in 
abnormal activation of the hypoxia pathway with a risk of developing tumors, most commonly 
PGLs (53). The disease is inherited autosomal dominantly and with a relatively high risk of 
metastatic disease (31-71%) (53).  
SDHA (OMIM 600857) found in 5p15, encodes a subunit of the succinate dehydrogenase 
complex (53). Mutations in SDHA can give rise to the PGL5 syndrome which includes PPGL 
disease (60, 61). Mutations on both alleles will give rise to Leigh syndrome which includes 
neurodegeneration and cardiomyopathy (53, 62).  
1.8.1.9 TMEM127 (OMIM 613403) 
TMEM127 is a tumor suppressor gene encoding transmembrane protein 127 which is involved in 
the signaling pathway of mTOR (mammalian target of rapamycin) (45, 63). When TMEM127 is 
absent following an inactivating mutation, mTOR phosphorylation is activated. TMEM127 
mutations give rise to familial PCC (45).  
1.8.1.10 VHL (OMIM 608537) 
The tumor suppressor gene VHL, located in chromosomal region 3p25, encodes two different 
proteins pVHL30 and pVHL29 the first active in the cytoplasm and the second in the nucleus. Both 
proteins are involved in the degradation of hypoxia inducible factor (HIF) (45). When mutated, 
this will lead to loss of function of the VHL protein which results in dysregulation of the hypoxic 
response and in turn, will give increased angiogenesis, proliferation and other tumor promoting 
changes (45). Germline mutations of VHL give rise to von Hippel-Lindau (VHL) syndrome with 
autosomal dominant inheritance. Except for PPGLs, the disease includes other tumors of different 
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organs such as renal cell carcinoma, tumors of the central nervous system and retinal 
haemangioblastomas (45, 64). Besides mutations of the VHL gene, hypermethylation of the VHL 
promoter has been reported and was also inversely correlated to VHL expression further 
emphasizing the role of VHL in PPGL development (65). 
1.8.1.11 Additional susceptibility genes reported in recent years 
As time progressed, several additional susceptibility genes have been proposed as a result of 
persistent research and improved sequencing methods. Nevertheless, new genes with potential 
susceptibility features are expected since there are still PPGLs without apparent explanation 
regarding tumor development. Among the more recently proposed genes are EGLN2, MDH2, 
GOT2, SLC25A11, DLST, H3F3A, DNMT3A, MET, MERTK, MEN1 and KMT2D (17, 38, 66). 
1.8.2 Genes associated with sporadic PPGL 
Non-constitutional mutations are a frequent event in PPGLs and several of the common 
susceptibility genes have also been found somatically mutated in PPGLs, eg NF1, VHL, EPAS1, 
RET and MAX (67-70). In addition, several somatic mutations of genes not constitutionally 
coupled to PPGLs have been linked to PPGL disease and are furthered explained below (17). 
1.8.2.1 ATRX (OMIM 300032) and TERT (OMIM 187270) 
Telomere maintenance mechanisms have been investigated in PPGLs and are believed to be 
associated with metastatic PPGL disease (71).  The ATRX gene is located on the X chromosome 
and plays a role in telomere maintenance (72) related to alternative lengthening of telomeres 
(ALT), an additional way of achieving unlimited proliferation (71, 73). Somatic ATRX mutations 
have been proposed as drivers in several cancers including neuroblastomas and were also found 
in PPGLs related to aggressive disease and SDHB mutations (72). Also, TERT expression, TERT 
structural variants and TERT promoter mutations have been reported in PPGLs further 
emphasizing the potential role of telomere maintenance mechanisms (71). 
1.8.2.2 BRAF (OMIM 164757) 
The proto-oncogene BRAF, located in chromosomal region 7q34, will code for the protein kinase 
BRAF active in the MAPK pathway (74). Somatic mutations of BRAF in PPGL were first 
detected by Luchetti et al. (75) in 2015 and will lead to a continuous activation of this pathway 
by increased kinase activity leading to cancer formation (74, 75). BRAF mutation have previously 
been shown in several other cancer types and the most common mutation is V600E (75).  
1.8.2.3 HRAS (OMIM 190020) 
Somatic hotspot mutations of the proto-oncogene HRAS, in chromosomal region 11p15.5, are 
recurrently seen in PPGL (75). The somatic mutation will lead to continues activation of RAS 
which cannot be reached by inhibitory signals resulting in pro tumor developing conditions (75). 
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HRAS mutations in PCCs were first reported as early as 1992 (76) and have been confirmed in 
succeeding studies (75, 77, 78).  
1.8.2.4 KMT2D (OMIM 602113) 
Juhlin et al. recently found KMT2D, a gene located in chromosomal region 12q13.12, to be a 
recurrently mutated gene in sporadic PCCs (38) but not in PGLs (79). The KMT2D protein works 
as a histone methyltransferase (80) and has been reported with both tumor suppressing and 
oncogenic qualities (38). Mutations of this gene are known in non-Hodgkins lymphoma and other 
tumor types. It is believed that aberrant KMT2D function in PCC affects the levels of histone 
methylation in PCCs, and possibly also stimulates increased migration of PCC cells (38).  
1.8.2.5 Additional somatically mutated genes in PPGLs 
In addition to the somatically mutated genes above several other genes have been reported 
somatically mutated in PPGLs, e.g. CDKN2A, TP53, MET, IDH1, and FGFR1 (17, 81-83). 
 
1.9 CLUSTERING OF PPGL BASED ON GENE EXPRESSION PATTERNS AND 
ONCOGENIC PATHWAYS 
PPGLs can be divided into clusters based on mRNA expression profiles. Initially, two clusters 
were identified, the pseudohypoxia group and the kinase signaling group (68, 84), suggesting two 
different pathways involved in PPGL development. In 2017 two additional subtypes, the Wnt-
altered group and the cortical admixture group, were suggested based on an unsupervised 
consensus clustering (85). The last subtype, however, is sometimes excluded due to uncertainty 
regarding its accuracy (86). 
1.9.1 The pseudohypoxia group 
The pseudohypoxia group (sometimes referred to as Cluster 1) comprises tumors whose 
underlying genetics will lead to a hypoxic response regardless of whether the milieu having 
normal oxidation levels (26). In this group tumors with mutations in VHL, SDHx, EPAS1 (HIF2A) 
(47, 68, 87), and possibly also in EGLN1 and FH, are included (26, 88). Similar to the response 
of acute hypoxia, tumor development in these tumors are secondary to stabilization of 
transcriptions factors (HIFs) that will bolster cell growth, migration of cells, energy metabolism 
and other conditions favorable for cell survival and build up (88, 89). HIF is built up of one α-
subunit and one β-subunit. The α-subunit will regulate the activity of HIF, as the expression of 
the β-subunit is constant (26, 89).   
In normal oxygen conditions HIF-α will be hydroxylated by members of the EGLN (aka PHD) 
family, a reaction that needs α-ketoglutarate and O2 to generate hydroxylated HIF, as well as the 
by-products succinate and CO2 (26). The hydroxylation of HIF-α makes it recognizable for VHL 
binding. VHL in turn is part of the E3 ubiquitin ligase complex and the binding will result in the 
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proteasomal degradation of HIF-α. Under hypoxic conditions as well as in pseudohypoxia a 
change in this pathway result in HIF-α not being sent to degradation and instead, is free for 
binding to HIF-β, leading to activation of genes favoring angiogenesis and cell survival etc (26). 
 
This activation can be the result of a HIF-2α (EPAS1) mutation, EGLN1 mutation or a VHL 
mutation (26, 88). Another possible way of activating the pseudohypoxic pathway is through 
SDHx mutations. This is brought by an excess of succinate from the TCA cycle when the SDH 
Figure 7. Illustration of Pseudohypoxia subgroup. To the left is the pathway in normal 
oxygen conditions where HIF-α is hydroxylated by EGLN following VHL binding for 
degradation. To the right the pseudohypoxia pathway is shown. Downregulating mutations 
are shown with red line and activating mutation are shown with red circle. Without being 
hydroxylated or bound for degradation HIF-α is free to act as a transcription factor 
together with HIF-β resulting in increased angiogenesis, cell survival and energy 
metabolism. In the TCA cycle, mutations of SDHx genes cause succinate to accumulate and 
inhibit EGLN, further increasing the function of HIF-α. HIF-α will also downregulate the 
SDH complex. The illustration is inspired by Welander et al. (26) and Dahia et al. (88). 






complex is not able to transform succinate to fumarate due to malfunctioning SDHx complex 
(26). The succinate will leave the mitochondria and work as an inhibitor of the hydroxylation of 
HIF-α, again resulting in unhydroxylated HIF-α connecting with HIF-β giving increased 
expression of genes important for tumor development (26). Unhydroxylated HIF-α has also been 
proposed to negatively affect SDHB, further decreasing SDH activity in the mitochondria (26).  
The pseudohypoxic pathway is shown in Figure 7.  
1.9.2 The kinase signaling group 
The kinase signaling group (sometimes referred to as Cluster 2) includes tumors related to Ras 
mediated mitogen-activated protein kinas (MAPK) pathway and PI3K/AKT pathway where 
activation result in cell growth, cell proliferation and cell survival. These pathways are commonly 
involved in human cancer (26, 90, 91). Tumors with mutations in NF1, RET, MAX, TMEM127 
and HRAS are often included in this subgroup (47, 68, 92).  
Some of these gene products work as inhibitors of different steps in these pathways. NF1 will 
inactivate RAS, TMEM127 negatively regulates mTOR (26) and MAX regulates the oncogenic 
signaling by MYC (45). Mutations of these genes will lead to increased activation of different 
stages in the MAPK pathway, PI3K/AKT pathway or MYC oncogenic functions (88). RET, 
however, is an oncogene at the top of the MAPK and PI3K/AKT pathways and mutations of RET 
will activate the pathways (26). Mutations of HRAS, a part of the RAS family will also lead to an 
activation of MAPK and P13K/AKT pathways (77). Additionally, it has been shown in other 
tumors that activation of MYC together with mTOR will upregulate protein translation by 
inhibiting 4EBP1 (88). mTOR activation as well as MYC activation have also been found to 
trigger HIF signaling, resulting in increased glycolysis. This constitutes one example of 
overlapping between clusters, as HIF activation is more commonly associated with the 







Figure 8. Illustration of MAPK pathway and PI3K/AKT pathway. To the left; the pathway 
when it is not activated by cluster 2 mutations. Tumor suppressors such as NF1, MAX and 
TMEM127 are suppressing the pathway activity. To the right; the pathways are activated by 
either activating mutations (shown by red circle) or by inactivation of one of the tumor 
suppressors (shown by red line). Activation of the pathways will lead to cell survival, cell 
proliferation, lipid synthesis and DNA synthesis. By inhibiting 4EBP1, activation will also 
lead to protein translation and by activation of HIF, glucose uptake will increase. The 
illustration is inspired by Welander et al. (26) and Dahia et al. (88). Some steps are not 
shown in this illustration.  
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1.9.3 The Wnt-altered group  
The Wnt-altered group is one of the later added subgroups, including only sporadic PPGLs (85). 
It is distinguished by high expression of genes involved in the Wnt- and Hedgehog signaling 
pathways (85). Tumors with MAML3 mutations and also some tumors with CSDE1 mutations are 
found in this subgroup  (85).  
1.9.4 The cortical admixture group  
The cortical admixture group was found to have raised expression of genes previously associated 
with adrenal cortical tissue as well as PPGL markers (85). MAX mutated tumors have been found 
in this group and it has been hypothesized that multifocal tumors may be responsible for the 
combination of cortical and PPGL expression markers (85). It has been debated whether this 
subgroup is a true subgroup or just caused by low representativity of tumor cells in the 
investigated samples (86) and it is therefore sometimes excluded.    
 
1.10 TELOMERASE ACTIVATION IN ADRENAL TUMORS 
One of the important functions of a cancer cell is immortalization (7). However, as the DNA 
replication proceeds, the telomere, consisting of telomere repeats of TTAGGG, is shortened, 
limiting the possible number of cell divisions for each cell (93). As a mechanism for cell 
immortality, cancer cells often acquire the ability to unlimited number of cell division. One way 
of doing so is through telomere elongation, which can be carried out through telomerase activation 
(94). 
Telomerase is a DNA polymerase that adds telomere repeats to the end of the telomeres. In most 
healthy cells, telomerase is not activated however in a majority of cancers it has been found at 
increased levels (95). Telomerase is composed of several proteins, most importantly a catalytic 
subunit called telomerase reverse transcriptase (TERT), which is encoded by the gene with the 
same name (TERT OMIM 187270), and the telomerase RNA encoded by Telomerase RNA 
component (TERC) (93, 96). The common way for telomerase activity is believed to be through 
upregulation of the TERT subunit which has been reported in several tumor types. TERT 
upregulation through TERT mutations were first shown in malignant melanomas (97, 98) but 
since then, it has been established in several tumor types including endocrine tumors (99-103). 
The two common mutations found in the TERT promoter are C228T and C250T. The C228T has 
been found in adrenal tumors, in ACC and more rarely in PPGLs (104, 105). Also, structural 
variants have been detected in PPGLs with metastatic disease (106).  
In addition to telomerase activation and TERT related genetic aberrations, ATRX mutations, 
related to ALT mechanism (107), have been found in PPGLs (71, 72) further underlining the 
importance of the telomere maintenance mechanisms.   
 
 21 
1.11 CHROMOGRANIN A AND CHROMOGRANIN B 
CHGA is a protein commonly found in secretory granules in many neuroendocrine, endocrine 
and nervous system tissues, where it is involved in regulation of synthesis and secretion of the 
signaling molecules (108). This protein is used as an immunohistochemical marker for PPGLs, 
where strong staining indicates PPGL disease (17). In addition to CHGA, two other 
chromogranins, Chromogranin B (CHGB) and Chromogranin C, have been found in similar 
locations, and all three types have been shown present in PCCs (109). During the release of 
catecholamines and neuropeptides into the blood, chromogranins also pass into the blood stream, 
making chromogranins potential diagnostic serum biomarkers for neoplasms in these tissues 
(109). Indeed, CHGA in blood has been proposed as a marker for neuroendocrine tumors and 
blood CHGA has been reported elevated in up to 80% of PCC patients (108), however, others 
report less desirable sensitivity and specificity in this measurement (110). Also, circulating 
CHGB has been shown to be a rather sensitive marker for PCC, however not as sensitive a marker 
as CHGA (109). Altogether, measuring of catecholamines and metabolites has been found more 
efficient than serum CHGA and CHGB measurement in the diagnostics of PCC (108). In addition 
to the serum investigations, chromogranins, including CHGB, have been further studied with 
immunohistochemistry investigating the differences between benign and metastatic disease, 
however no significant difference was observed (111). A recent finding further emphasized the 
role of CHGB, as it was suggested to be of importance in the differentiation of chromaffin cells 
(5).   
1.12 CALCIUM CHANNELS AND THEIR POTENTIAL ROLE IN TUMORIGENESIS 
Low-voltage-activated T-type Ca2+ channels are calcium ion channels with the specific trait of 
being activated at low membrane potential allowing them to play a part in several different 
processes inside the cell depending on the type of tissue (112). For instance, in neuroendocrine 
tissue they are involved in the release of hormones (112). 
There are three different isoforms of T-type Ca2+ channels referred to as Cav3.1, Cav3.2 and 
Cav3.3 and encoded by CACNA1G, CACNA1H and CACNA1I respectively (112). T-type 
channels are plasma membrane proteins and comprise four hydrophobic domains called Domain 
I-IV. Every domain consist of six helices that passes through the membrane (see figure 9) and the 
ion selectivity and ion conductivity works through the fragment of the protein connecting the two 
last helices of every domain (112). 
Channelopathies, where dysregulation of the channels lead to sickness, exists and appear to be 
made up of both loss-of-function and gain-of-function alterations (112). Due to the importance 
of these channels in physiological processes in the body and in cell functions, mutations giving 
changes in the channels are believed to be potentially harmful (112). 
Many different mutations of CACNA1H have been found in patients with epilepsy syndrome and 
it has been suggested that this gene has a role in the pathophysiology behind the illness (112-115). 
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Also, CACNA1H has been proposed to play a part in several other diseases such as chronic pain, 
neuromuscular disorder and autism (112). 
Using whole exome sequencing, CACNA1H mutations were found in several cases of PA and 
found to have an impact on intracellular Ca2+
 
by the mechanism of increased channel activity 
(37). The increase of intracellular Ca2+ in turn will give an increase of aldosterone production, 
resulting in hypertension (37).  
T-type Ca2+ channels have also been linked to several tumor types (116-118). For instance, in 
ovarian cancer, expression of T-type Ca2+ channels have been found increased and related to 
proliferation (119). In a breast cancer cell line, knock down of Cav3.1 and Cav3.2 lead to a 
decrease of proliferation, suggesting a role for T-type channels in breast cancer proliferation 
(120). 
In rat pheochromocytoma PC12 cells, expression of Cav3.2 was found to be upregulated after the 
cells had been exposed to hypoxia (121). It was also suggested that this is a result of HIF binding 




Figure 9. Schematic illustration of low-voltage-activated T-type Ca2+ channel consisting of 
four domains and every domain consisting of six helices passing through the plasma 
membrane. The illustration is inspired by Scholl et al. (37). 
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2 AIMS OF THE PROJECT 
 
General aims of the projects in the study plan 
- To further clarify the genetic and epigenetic background of adrenal tumors and the possible 
associations of such alterations to clinical phenotypes and outcome 
 
- To investigate possible improvements of clinical handling for patients with adrenal tumors 
concerning underlying molecular alterations  
 
- To further investigate genetic predisposition in PPGL 
 
Specific aims of the projects in the study plan 
I To investigate if mutations in the NF1 gene could be predicted by immunohistochemistry as 
a tool to recognize cases in need of further examination  
II To investigate genetic and epigenetic events as potential underlying mechanisms for 
increased TERT expression and potential contributors in tumor development 
III To evaluate the effects of molecular and genetic aberrations on PPGL clinical features  





3 MATERIAL AND METHODS 
3.1 MATERIAL 
In this thesis, tumor and non-tumoral tissue samples are used to answer our research questions.  
The study material is most commonly collected from the endocrine biobank at Karolinska 
University Hospital but also from biobanks at co-operative universities at Linköping and Yale. In 
1986 the endocrine biobank project at Karolinska University Hospital was introduced. Patients 
operated for endocrine tumors were offered participation in research projects at the Karolinska 
University Hospital. Tissue and blood samples of consenting patients were collected during 
surgery. After surgical removal of the tissue, the parts designated for research are snap frozen in 
liquid nitrogen and kept in -80 °C.   
Frozen tissue samples were used for extraction of DNA and RNA. DNA extraction was performed 
using DNeasy DNA isolation kit (QIAGEN) and RNA extraction was performed using mirVana 
miRNA isolation kit (Ambion/Invitrogen).  
Formalin fixed, paraffin embedded tissue samples were cut in approx. 4 µm sections and mounted 
on slides to be used for immunohistochemical investigations.  
Usage of patient material for the present study is approved by ethical committees at Karolinska 
Institutet, Solna, Linköping University, Linköping and Yale University, New Haven.  
3.1.1 Cohorts of tumors of adrenal cortex 
In Paper III tumors of the adrenal cortex are investigated. The cohort consisted of 27 ACCs from 
Karolinska University Hospital and 11 ACCs from Yale University. Tumors had previously been 
assessed regarding the clinical parameters age at diagnosis, patient sex, tumor size, tumor weight, 
Ki-67 index and ENSAT stage.  
Eight adrenocortical hyperplasia samples were used only as reference tissue. 
3.1.2 Cohorts of tumors of adrenal medulla and paraganglion 
A cohort of totally 95 PCCs and 14 PGLs was used in Paper I, II, IV and V. Samples included in 
each study were chosen based on access of study material (DNA, RNA or formalin fixed tissue). 
Most samples had previously been investigated for mutations in several of the known 
susceptibility genes (Table 1) (38, 47, 79, 87, 100, 122-124). Also, a majority of the samples had 
previously been investigated with whole-transcriptome analysis using the GeneChip Human 1.0 
ST array (Affymetrix) (47, 87) and this data was also used in Paper IV and V. PASS score was 
previously determined for some of the cases through the clinical routine handling, however, in 
Paper IV a majority of samples were re-evaluated concerning PASS criteria. Most tumors had 
also been investigated for clinical parameters such as age at diagnosis, patient sex, tumor size, 









3.2.1 PCR and qPCR  
The method of using a PCR approach for amplifying segments of the DNA was first invented in 
1984 (125). Eight years later the qPCR method was developed, based on the original PCR method 
but with the ability to detect the PCR product, allowing it to be quantified (125). 
The PCR process is divided into repetitive cycles of temperature variations. Three main stages 
make up the PCR process starting with denaturation to separate the DNA strands (125). The 
denaturation is followed by hybridization of primers which allow the primers to align to the DNA 
and the last stage is elongation and polymerization where the DNA strand is copied (125). 
Quantification is performed using fluorophores and, in every cycle, fluorescence will be detected. 











Number of tumors 
with mutations of 
unknown 
constitutional status 
NF1 5 16 1 
RET 9 4 0 
VHL 1 2 1 
SDHB 5 0 0 
SDHA 2 0 0 
SDHC 0 0 0 
SDHD 0 0 0 
SDHAF2 0 0 0 
TMEM127 1 0 0 
MAX 0 1 0 
KIF1B 1 1 0 
EPAS1 1 3 4 
EGLN1 1 0 0 
MEN1 0 0 0 
HRAS 0 0 5 
KMT2D 2 10 1 
TERT (promoter) 0 0 1 
BRAF 0 0 0 
        
Table 1. List of genes investigated and mutations detected in our cohort 
of PPGLs at Karolinska Institutet. 
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bind to the double-stranded DNA and the amount of fluorescent, which is proportional to the copy 
number, is measured (125). One example of this is SYBR Green.  
The alternative method of using fluorochromes on probes is more specific as the probe will only 
bind to the amplified sequence of the DNA (125). This is the method used in TaqMan assays. The 
probe, in this case, is labeled with a “donor” and an “acceptor”. The donor is a fluorophore that 
will emit fluorescence and the acceptor will quench this signal as long as they are close to each 
other (125). This results in the fluorescence only being detected when the donor and the acceptor 
is parted which occurs when the Taq polymerase are amplifying the DNA sequence, thus the 
emitted fluorescence is correlated with the number of amplicons (125). 
3.2.2 DNA analysis 
3.2.2.1 Sanger sequencing 
Using PCR, multiple copies of a sequence are generated (125). These sequences are later used to 
distinguish the genetic code using the Sanger sequencing method, first described in 1977 (126). 
The DNA is first denatured, separating the two strands. Primers to the specific region of interest 
are then attached to the DNA leading to the upbuild of a new copy of the region. However, in the 
mixture of bases to be added, chain-terminating bases are added creating DNA sequences of 
different length. The sequences can then be separated and arranged based on their lengths. The 
chain-terminating bases will also be labeled with fluorescent markers, specific to the base type. 
This will enable the sequence reading (127) and the results are visualized in chromatograms 
where different bases are represented by different colors (Figure 10). The method was used in 
Paper III and V and the sequencing was performed by core facility KI gene at Karolinska Institutet 
(KI). Primers were either commercially available or designed in house using Primer3 
(https://bioinfo.ut.ee/primer3-0.4.0/). Sequencing results were assessed manually using Chromas 
2.6.6 1998-2018 and Genome Compiler Corporation, Los Altos, CA, 2015. 
 
Figure 10. Example of chromatogram, visualizing the genetic sequence by a 
unique color for each base. 
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3.2.2.2 Bisulfite Pyrosequencing 
In Paper II and III, Pyrosequencing was used to determine CpG methylation densities. This 
method is a sequencing-by-synthesis method using bisulfite treated DNA. The bisulfite treatment 
changes unmethylated cytosine to uracil at the CpG sites making it possible to compare the 
amount of methylated versus unmethylated CpG sites (128). Biotin labelling of the DNA 
sequence is used to connect the DNA to streptavidin beads, securing the DNA to be fixed and not 
washed away. As the sequencing takes place, different bases are added separately and when a 
base is used, pyrophosphate is freed and will in turn be converted to ATP to be used in a light 
producing reaction. The light produced will be proportional to the pyrophosphate initially freed 
and also to the number of nucleotides that were used in the synthesis (128). Primers were 
designed in‑house with PyroMark Assay Design software version 2.0 (Qiagen AB). A 
PyroMark Q24 system was used for the pyrosequencing reactions and PyroMark Q24 2.0.7 
software (Qiagen AB) were used for the data analysis generating one methylation density per 
CpG position per tumor. A mean methylation density (MetI) per tumor was calculated manually 
as a final step. 
3.2.2.3 Copy number analysis 
In Paper III copy number was assessed using a qPCR TaqMan approach. In this method, copy 
number is determined based on comparison to a reference sequence with known copy number 
(129). A commercially available TaqMan assay was used and RNaseP served as reference. 
Samples were run in quintuplicates to eliminate the influence of pipetting differences. CopyCaller 
v2.0 was used to assess the results.     
3.2.2.4 Telomere length 
Relative telomere length was estimated in Paper III. A qPCR method was used with DNA as 
starting material. In this method, first proposed by Cawthon in 2002 (130), primers for human 
telomere (TEL) are used to obtain telomere amplification product and the results are compared to 
a reference gene (131). Samples were run in triplicates to minimize the influence of pipetting 
errors.  
3.2.3 RNA analysis 
3.2.3.1 Gene expression using reverse transcription qPCR (RT-qPCR) 
Gene expression were studied in paper IV and V. In these papers RT-qPCR was used to determine 
the expression of certain genes. To do so, RNA was converted to cDNA to assure the stability of 
the study material. TaqMan assays used in the studies are commercially available. The 
endogenous control, B2M, was chosen based on previous research of endogenous controls 
investigating the smallest expressional variation in PPGLs (65). Results were converted according 
to 2 -̂deltaCt and reported as relative expression. 
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3.2.4 Protein analysis 
3.2.4.1 Immunohistochemistry (IHC) 
Immunohistochemistry is a sensitive method to detect antigen in tissue samples. The great 
strength of this method is the ability to correlate antigen to a position in the tissue section. In our 
studies, tissue samples were formalin-fixed, paraffin-embedded and mounted on histological 
slides. During the fixation a majority of the antigens in a tissue section will have their structure 
changed, making antibody detection difficult. To solve this problem, methods for antigen retrieval 
are included in the protocol.  
In this thesis Xylene is used to dissolve paraffin and antigen retrieval is obtained through citrate 
buffer pH 6 at high temperature. Endogenous peroxidase is blocked with hydrogen peroxide 
solution, to allow for DAB based developing method (132). To reduce background staining, BSA 
blocking is performed (133). Endogenous biotin can be blocked using the Avidin-Biotin-blocking 
system. Slides are then incubated with primary antibody followed by secondary antibody 
incubation. Peroxidase activity is induced using DAB-chromogen where the reaction H2O2 to O2 
and H2O resulting in a brown color where the antigen is found (Figure 11). Counterstaining with 
hematoxylin is performed as a final step (132). 
 
3.2.5 Statistical analyses and illustrations 
SPSS 23, 24, 25, 26 (IBM SPSS, Armonk, NY, USA) and Statistica (Statsoft, Tulsa, OK, USA) 
were used for statistical calculations and graphic presentations. Illustrations were made using 
PowerPoint (Microsoft Office) and Inkscape 0.92.  
Figure 11. Example of immunohistochemical staining. Brown color indicates that the antigen 
has been identified by the antibody. The blue color comes from counterstaining with 
hematoxylin.   
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3.3 ETHICAL CONSIDERATIONS 
In this thesis, tumor tissue from patients with adrenal tumors are investigated. Clinical parameters 
are studied and compared to different aspects of the tumor biology and genetics. Also, blood 
samples were collected from the participating patients. All patients undergoing surgery for an 
adrenal tumor or a paraganglioma have been asked to participate in the research. The patients are 
then able to accept or decline participation.  
Ethical approvals have been granted from the local ethical committees. Ethical considerations 
were further reflected upon during participation in course “Philosophy of Science and Research 
Ethics”. 
The basic goal of the research is to acquire knowledge that can help patients affected with adrenal 
tumors. If successful, this will gain future patients with these tumor types. The purpose of the 
research is consequently with good intention which is a basic quality of good ethics in research.  
-  Patients were informed both by written and oral information regarding the meaning of 
participation. This is to improve patient understanding and make sure everyone really knows 
what they are agreeing to.  
-  Patients had full right to decline participation or to withdraw at any time.  
- Patients that accepted participation did not get different treatment than patients who declined, 
and diagnostics for clinical purposes was always prioritized before research, which is 
important from an ethical aspect.  
-  Participants were not rewarded in any way which is important as it may influence people in a 
way that is not ethically appropriate.  
- Patients in the study did not undergo more or less painful or psychologically tough procedures 
than patients that were not participating in the study. Blood samples were collected during 
general anesthesia and no harm was therefore caused.  
-  Tumor tissue and patient information is kept de-coded to retain patient anonymity.  
Accidental findings are an ethical issue to be reflected on. Several genetic tests are performed on 
the tissue samples and the ethical issue appears with findings that, if known to the patient and the 
physician, could benefit the treatment of the patient. On the one hand, it is ethically right to inform 
the treating physician of the findings, giving the physician the chance to potentially prohibit 
diseases in the future of the patient. On the other hand, the patient’s decision to participate or not 
in a research project should not be influenced by a possibility of individual benefits concerning 
treatment. This would create unethical praise for participation.  From a different standpoint, the 
patient may not want to know about the accidental finding and should have the right to be spared 
such information, if that is their wish.  
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Also, it is important to know that research findings of potential clinical value need to be confirmed 
before translation to clinical practice can be initiated. Consequently, research findings cannot be 
used as such in clinical practice but need to be reassessed in clinical routine testing.  
In our current ethical permit, the question about incidental finding is covered, giving the patient 
information from the beginning of participation that accidental findings, affecting their health in 
a way assessed as most relevant, will be communicated to their treating physician with referral to 
relevant clinical field such as clinical genetics.  This gives the patient a chance to reflect, to be 
prepared and also the possibility to decline such information.  
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4 RESULTS AND DISCUSSION 
4.1 PAPER I. IMMUNOHISTOCHEMICAL NF1 ANALYSIS DOES NOT PREDICT 
NF1 GENE MUTATION STATUS IN PHEOCHROMOCYTOMA 
 
Constitutional NF1 mutations are frequently seen in PCC. In such cases the predisposing 
mutation gives rise to neurofibromatosis type 1 (NF1), a familial tumor syndrome associated 
with PCCs and other manifestations such as different skin abnormalities. By investigating PCCs 
for somatic alterations in predisposing genes, NF1 was found to have frequent copy number loss 
correlating with reduced NF1 mRNA expression and somatic truncating NF1 mutations (67, 
122). These observations identified NF1 as the most frequently somatically mutated gene in 
PCC and suggested a tumor suppressor mechanism of loss of function. Detection of NF1 
mutations could be clinically relevant, however, the large size of the gene with over 50 exons 
(Figure 12) made genetic sequencing a burdensome method. In the case of SDHx tumors, IHC 
for SDHB had been reported as a good tool to detect SDHx mutated tumors (134) suggesting 
that this method might be successful in detecting other mutations as well.     
In Paper I (135), immunohistochemical analysis was used to investigate the possibility to predict 
NF1 mutation status by analyzing the protein expression in tumor tissue. Sixty-seven patients, 
18 patients with NF1 mutation (Figure 12) and 49 patients without NF1 mutation, were 
investigated using immunohistochemistry. Results from the staining showed that 44 out of 67 
PCCs lacked staining, including 13 out of 18 with NF1 mutation.  The remaining 23 PCCs 
showed staining for NF1. Only five of the NF1 mutated cases had NF1 staining showing that a 
majority of the mutated cases could be detected using this method, however as the majority of 
the non-mutated cases was also found without staining for NF1 the specificity of this method is 
low.  
No apparent explanation was found regarding the reason for retained staining in the mutated 
cases, nor for the lack of staining in the non-mutated cases. Retained staining, however, is not a 
guarantee for retained function and activity. It is possible that faulty proteins might be found 
and stained even though they lack ordinary functions. Also, non-mutated cases could suffer from 
other genetic, epigenetic, translational or post-translational changes resulting in lost function of 
the protein and potentially explain the lack of staining in non-mutated cases. 
Nonetheless, all the normal medulla that could be seen in the tumor slides and also totally normal 
samples were also negative for NF1 staining, raising the relevant question of whether the protein 
is present and detectable under normal conditions. If the protein is not present in the normal 
tissue, the gain of protein in some of our tumor slides is an interesting finding that could be 




Another interesting observation was that NF1 immunoreactivity was particularly pronounced 
around the blood vessels (Figure 13) and in proximity to the tumor capsule. There are only 
speculations to explain this, including subclonal expansions within the tumor or different 
mechanisms for the protein to be more detected in these areas but without an increased function.  
It is also important to remember that only one antibody has been used in this study and the 
antibody specificity and sensitivity can mislead results if not optimal for the target protein. In 
this case, the antibody was tested in different control materials with satisfying results and also a 
DotBlot experiment was performed to minimalize the risk of antibody caused mislead results.  
The results of the study are in line with previous findings in a smaller cohort where NF1 
immunostaining was shown not to be suitable as a marker for NF1 mutations (67).   
Figure 12. Schematic illustration of the NF1 gene and the location of the NF1 mutations in 
the cohort used in the study. Symbols of the mutations illustrate mutation types and 
immunohistochemistry staining for NF1 is shown in the lower row for the mutated cases (0 = 
no immunoreactivity, +/- = focal areas with immunoreactivity, + = uniformly weak 
immunoreactivity and ++ = moderate/strong immunoreactivity). The arrow is pointing out 
location of antibody binding. This image is previously published in Paper I (135) and 





4.2 PAPER II. TELOMERASE REVERSE TRANSCRIPTASE PROMOTER 
HYPERMETHYLATION IS ASSOCIATED WITH METASTATIC DISEASE IN 
ABDOMINAL PARAGANGLIOMA 
 
Telomerase activation is seen in several tumor types, leading to telomere elongation and cell 
immortalization.  One possible way of telomerase activation is through mutations of the TERT 
gene promoter (Figure 14), which has been reported in PPGLs together with telomerase 
activation. Beside these mutations, other mechanisms for TERT upregulation has been reported. 
In Wang et al. 2016, hypermethylation of the TERT promoter in medullary thyroid carcinoma was 
reported and found to correlate to TERT mRNA expression and telomerase activity (136).   
In this letter to the editor (137), methylation of the TERT promoter was investigated in search 
for other mechanisms of telomerase activation. TERT methylation was quantified by 
Pyrosequencing in 90 PPGLs, investigating two different regions (Figure 14). Region A was 
previously reported in thyroid carcinomas coupled to worse patient outcome (136) and Region 
B was previously investigated in vitro where low methylation was suggested important for TERT 
expression (138).  
The results of the study showed that high methylation of Region A was associated with 
metastasis and relapse in PPGLs and PGLs alone. In Region B, methylation was found to be 
higher in Cluster 1 tumors compared to Cluster 2 tumors. No significant difference in 
methylation levels was observed between PPGLs and normal adrenal samples.  
Figure 13. Immunohistochemical analysis of a PCC tumor where 
NF1 immunoreactivity was seen more pronounced around the blood 
vessels. Republished with permission. 
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The increased methylation levels could be part of a hypermethylator phenotype in malignant 
tumors. Another possibility is that hypermethylation in this region could be the result of 
alterations of different pathways also associated with malignancy. Malignant behavior in PPGLs 
is difficult to predict and patients with increased risk for malignant disease could benefit from 
different treatment options and more intense follow-up. Supporting the potential significance of 
a TERT based diagnostic tool is the finding of structural rearrangements in metastatic PCCs 
reported by Dwight et al. in 2018. In this case, telomerase activation is thought to result from 
super-enhancers rearranged close to the TERT promoter (106). TERT promoter 
hypermethylation has since been investigated in a recent study by Job et al. 2019 reaching 
similar conclusions that TERT promoter mutation status and TERT promoter methylation status 
could be of importance in clinical practice to identify tumors with high risk of metastatic 
development (139).  
 
4.3 PAPER III. TERT PROMOTER HYPERMETHYLATION IS ASSOCIATED WITH 
POOR PROGNOSIS IN ADRENOCORTICAL CARCINOMA 
 
Similar to Paper II, this study is focused to investigating alternative ways for telomerase 
activation, other than TERT promoter mutations (Figure 14). Telomerase activation has been 
reported in ACCs and only a minority of cases can be explained by hotspot TERT promoter 
mutations (100). Methylation levels, copy numbers and telomere length were investigated in a 
cohort of 38 ACCs in Paper III (140).  
 
TERT promoter methylation and copy number were both increased in the tumor tissue compared 
to normal adrenal tissue. Moreover, the results were further analyzed in relation to clinical data 
Figure 14. Schematic illustration of the TERT promoter region, showing the investigated regions for 
TERT promoter methylation. Hotspots for TERT promoter mutations are marked at their individual 
positions within Region B. TSS is indicating transcription start site and ATG is illustrating the 
translating start site. This figure is inspired by Figure 1 in Paper III (140). 
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where it was associated to worse clinical outcome. In detail, high promoter methylation in 
Region A was associated to metastasis or relapse, survival and higher ENSAT stage. TERT 
promoter methylation in Region B was inversely correlated to mRNA expression levels of 
TERT. Also, TERT mRNA expression was correlated to relative telomere length.  
In total, 70% of ACCs had either TERT promoter mutation or copy number gains (Table 2), 
concluding that TERT promoter alterations are frequent in ACCs. These mechanisms could 
explain the majority of the TERT expression seen in these tumors and potentially mean that 
TERT based diagnostic tools could be of use in the assessment of ACCs.  












1 No No Yes 
2 No No Yes 
3 No Yes Yes 
4 No No No 
5 No Yes No 
6 No No No 
7 Yes No Yes 
8 No Yes Yes 
9 No Yes Yes 
10 No Yes Yes 
11 No Yes No 
12 Yes No No 
13 No No Yes 
14 No Yes Yes 
15 No Yes Yes 
16 No Yes Yes 
17 No Yes Yes 
18 No Yes No 
19 No No Yes 
20 No No Yes 
21 No Yes Yes 
22 No Yes Yes 
23 No Yes No 
24 No No No 
25 No Yes No 
26 No Yes Yes 
27 Yes No Yes 
    
Table 2. Results of Paper III showing TERT promoter mutation status, TERT copy 
number status and Region A TERT methylation status of 27 ACCs. This table is inspired 




Telomere lengths were investigated in normal tissue and tumor tissue. No difference was found 
between tumors and normal samples, however that does not necessarily mean that the telomerase 
is inactive. Telomere length was correlated to TERT expression which could be expected as 
TERT expression will give rise to telomerase activity resulting in elongation of the telomeres. 
Also, shorter telomeres were found to be associated to worse outcome.  
TERT hypermethylation in Region A was found to a higher extent in ACCs with a worse clinical 
stage and outcome. This hypermethylation might be part of a general hypermethylation 
phenotype and should be further investigated in future studies and it might be developed into a 
prognostic tool which could be of value when deciding on treatment and follow up. In this study 
several possible mechanisms for telomerase activation has been found. Telomerase activation 
in turn is thought to enable replicative immortality, an important trait of a cancer cell. Our 
findings support that TERT expression can be caused by multiple factors.    
 
4.4 PAPER IV. MOLECULAR PROFILING OF PHEOCHROMOCYTOMA AND 
ABDOMINAL PARAGANGLIOMA STRATIFIED BY THE PASS ALGORITHM 
REVEALS CHROMOGRANIN B AS ASSOCIATED WITH HISTOLOGIC 
PREDICTION OF MALIGNANT BEHAVIOR 
 
Previous views on malignancy in PPGLs where tumors were divided in to benign or malignant 
tumors have recently been modified according to the current believe that all PPGLs have a 
potential to metastasize (17). In the light of the broad potential of metastatic disease, a marker 
for early detection of the minority that actually develop malignancy is urgently needed.  
Two acknowledged methods have previously been proposed for this purpose, focusing on the 
histological criteria for malignant behavior. The PASS score (examples in Figure 15), which 
only uses histological assessment, and the GAPP score which uses histology as well as Ki-67 
proliferation index determined by IHC and catecholamine production status. While these 
systems assess the histological characteristics of the tumor, their relationship to the underlying 
molecular background has not been revealed. In Paper IV (141), we attempted to determine 
whether expression of individual genes or gene signatures are associated with such features 
indicating malignant potential.  
Ninety-two PPGLs were assessed by the PASS criteria and the results were analyzed in relation 
to mRNA expressional profiles obtained from microarray data. A PASS score of 4 or higher was 




 Thirty-two PPGLs had a PASS score of 4 or higher, including all 8 cases with known 
malignancy. In an analysis between mRNA expressional profiles and PASS score, one gene, 
CHGB, showed the highest association to PASS score of all genes analyzed. Also, in the analysis 
of malignancy and mRNA expression profiles, CHGB was found to have the highest association 
between the two. CHGB was found to have decreased expression in PPGLs with malignant 
disease or with histology indicating aggressive behavior. The expressional results were 
confirmed using qPCR where TaqMan CHGB expression was also found to be decreased in 
metastatic disease. In The Cancer Genome Atlas (TCGA) cohort, similar results were seen, 
presenting downregulated mRNA expression in cases with relapse.  
In addition to CHGB, several genes of possible interest were found when looking at the 
differently expressed genes (DEGs) in cases displaying different PASS criterion. Specifically, 
the thirty most DEGs coupled to each PASS criterion were collected. Genes of particular 
interests associated with the histological patterns of the PASS criteria as well as previously 
reported as associated to cancer were chosen for further analysis. Of the genes chosen only 
CHGB expression was significantly associated with disease related survival, however, several 
other DEGs, besides CHGB, were associated with recurrence free survival including BTBD11, 
Figure 15. Examples of PASS criteria shown in histological images. Upper left: Large nests. 
Upper right: capsular invasion. Lower left: Adipose tissue invasion. Lower right: High cellularity. 
These images are previously published in paper IV (141) and republished with permission.  
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KIF23, HIST1H3B and BUB1B. Also, in an analysis of all significantly DEGs (cut-of 2800 
DEGs) for different PASS criterion Histone cluster 1 (HIST1) genes were recognized as 
commonly appearing. This finding together with the previous mentioned genes associated with 
recurrence free survival could be potential subjects for further analysis in the future, 
investigating their influence on aggressive behavior in PPGL disease.  
Still, the main finding of this study is the recognition of CHGB as the most differently expressed 
gene associated to malignant behavior and PASS score. As this association was also seen in IHC 
staining for CHGB and blood samples, this suggests a role for CHGB in clinical practice as a 
possible marker for increased malignant potential.  
 
4.5 PAPER V. CACNA1H CONSTITUTIONAL MUTATIONS AND DECREASED 
CACNA1H EXPRESSION IN PHEOCHROMOCYTOMAS  
 
PPGLs are tumors with extensive genetic background where approx. 40% have a constitutional 
mutation in one of several PPGL susceptibility genes. Yet, all is not known about the underlying 
genetics and new recurrently mutated genes are still being reported.  
In this study, data from previously performed whole-exome sequencing (WES) was investigated 
and re-analyzed. Two PPGLs out of 15 in the discovery cohort had variants in the calcium channel 
coding gene, CACNA1H, previously reported in aldosteronomas and PA. This gene was chosen 
for further investigations with Sanger sequencing of five focus areas, mRNA expression using a 
TaqMan assay and protein expression using immunohistochemistry. Ninety-seven tumors in total 
were investigated, including the 15 that were previously investigated by WES.  
In the Sanger sequencing we confirmed the two variants found in WES. Two additional variants 
were found in the clinic during the time of the study and in the TCGA cohort another three variants 
were found in PCC patients. In total seven variants in CACNA1H have been found in PCCs (Figure 
16) including four constitutional variants (variants detected in the cohort at KI) and three not 
determined in constitutional tissue (detected in TCGA).  This gene is particularly interesting as 
mutations believed to have functional consequences have been reported in PA (37) and 
adrenocortical tumors. Indeed, two of the variants found in PCCs, G1064R and I1430T, have 
previously been reported in PA and aldosteronomas respectively (142, 143). 
Figure 16. Schematic illustration of protein alterations in CACNA1H found in PCCs (upper 
row) and adrenocortical tumors (bottom row).  
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Expression of CACNA1H mRNA was investigated and the results showed lower expression in 
PPGLs than in normal adrenal samples. Lower expression was also seen in the protein expression, 
where the tumor tissue showed lower expression than normal adrenal medulla.   
Cluster 1 tumors were found to have higher CACNA1H expression than Cluster 2 tumors. Since 
the pathways of Cluster 1 tumors often result in HIF activation and CACNA1H have previously 
been reported as a target of HIF, this was of particular interest. However, as the CACNA1H 
expression in normal samples were higher than in tumor samples the exact mechanisms behind 
the altered CACNA1H expression and potential HIF activation is still unknown and additional 
mechanisms are believed to play a role. With that in mind, CACNA1H methylation densities were 
investigated using the TCGA database. CACNA1H methylation was found to moderately correlate 
to CACNA1H expression, suggesting methylation levels can affect the expression.   
The finding of CACNA1H variants in PCCs together with altered expressional patterns is a 
potentially interesting addition to the genetic background of these tumors and should benefit from 




In Paper I, we conclude that NF1 immunohistochemical investigations are not an efficient 
screening tool to distinguish NF1 mutated cases.  
In Paper II, we found that TERT promoter hypermethylation is associated with metastatic disease 
in PGLs. We conclude that TERT activating mechanisms could potentially play a role in the 
metastatic transformation in PGLs and is therefore a possible tool in the assessment of malignant 
potential.  
Paper III investigates the potential role of TERT alterations in ACCs. The conclusion is that 
different mechanisms, such as TERT promoter mutations and TERT promoter hypermethylation 
might contribute to the activation of telomerase, leading to more aggressive disease. This could 
be a potential target for future therapies.  
In Paper IV, CHGB was reported as the gene whose expressional pattern was most associated to 
metastatic disease. We conclude that CHGB is a possible marker for aggressive disease that can 
be used to detect cases with metastatic potential both before and after surgical intervention.  
Paper V recognizes seven variants in CACNA1H in PCCs. This gene was previously found 
mutated in PA. CACNA1H expression is moreover found decreased in PCC compared to normal 
adrenal tissue. We conclude that alterations of CACNA1H is a potential novel genetic event in 




6 POINTS OF PERSPECTIVES 
6.1 FUTURE RESEARCH AND CLINICAL IMPLICATIONS 
In this thesis, the molecular background of PPGLs is the main focus and even though exciting 
findings have been discovered there are still much unknown about these tumors. Two main 
questions have been of particular interest; Why do patients develop these tumors? and What 
decides if they develop metastatic disease? 
These questions are still not completely answered. Surely, in PPGLs constitutional mutations 
predispose to the disease in affected patients, the estimated proportion of heritable disease is up to 
40%. Also, in PPGLs, several somatic mutations in different genes have been found and proposed 
to be of importance for tumor development. Similar to many other tumor types, young age at 
diagnosis, bilateral disease and to some extent even metastatic behavior are signs of heritable 
disease. However, there are still young people affected by and even dying from these tumors where 
no constitutional mutation can be found. Future studies could potentially solve the underlying 
tumor mechanisms in these cases.  
While genome wide sequencing has been done in different studies for PPGLs, all has not been 
discovered. With the purpose of finding new potential mechanisms of tumor development, one 
way would be to collect cases without known genetic trigger and use these cases for whole genome 
sequencing (WGS) studies, including search for structural variants. 
Markers for PPGL tumors that are more prone to metastasize are needed to improve clinical 
handling of these patients. In Paper IV we investigated mRNA expression patterns in an attempt 
to find malignancy markers and proposed CHGB as a differentially expressed gene coupled to 
metastatic disease. This marker could be used in clinical work-up of these tumors, however, 
additional studies are always needed to confirm the findings.   
Also, in Paper II, TERT promoter hypermethylation was associated with metastatic disease in 
PGLs. This finding is a potential target for future therapies and could be subject to further studies. 
WGS on selected cases with metastasis could potentially recognize new genetic links to 
metastasis. Distinguishing those genes with potential to cause aggressive disease will elucidate 
the mechanism behind the metastatic course with potential targets for therapies.   
6.2 STRENGTHS AND LIMITATIONS 
Like in all research, it is not easy to draw conclusions based on a small group of study material. 
In the case of adrenal tumors, the rareness of the tumors will naturally limit the possible number 
of study participants and this is one limitation of our studies. However, even though PPGLs are 
rare, the cohort used in these projects is relatively large and something we consider a strength 
based on the circumstances. The reason for the advantage in cohort size is the great number of 
years of which our biobank has been active. In 1986 the biobank for endocrine tumors was 
initiated, not only assuring our cohort size, but also enabling the follow-up time to be very long 
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for some of the patients, giving the clinical data much credibility and increasing our chances to 
find interesting associations.   
In addition to the cohort size, the cohort has many other strengths in that it has been investigated 
in many different aspects. Previous studies have investigated the mutational status for most of the 
known susceptibility genes and expressional patterns have also been investigated for many of the 
tumors. The clinical data have been followed up on several occasions. One possible improvement 
would be to collect more tumors from the more recent years and investigate them in the same way 
as the current cohort. In that way we could not only validate our previous findings but also have a 
better chance of catching the whole truth concerning these tumors.  
As previously mentioned, one potential future study could involve WGS, including the search for 
structural variants. The lack of whole genome data in our cohort could be seen as a limitation as 
it is a gap of knowledge concerning our cases. Still, we consider the genetic knowledge of our 
cohort to be of good quality and in line with what is known from other research centers. One 
would therefore have to reflect upon cost-effectiveness when deciding on future testing on cases 
with already known triggers.  
Also, as mentioned before, the lack of in vitro studies is always a limitation when aiming to prove 
a functional relevance on genetic aberrations. This is, however, planned for in future studies 
regarding Paper V.  
Still, several strengths in our projects are worth mentioning. For instance, the access of normal 
control tissues from both patients with and without PPGL. Such normal tissues may sometimes 
be lacking from data bases where other genetic information regarding tumor genetics is broad. 
Also, the wide range of testing material, including different types of tissues used as controls and 
also the access to core facilities such as Sanger sequencing service performed by KI gene and IHC 
staining service at the Bioclinicum will all improve study results.    
Another strength in our projects is the broad experience of the contributors. In our research we 
cooperate with different parts of the clinical field, such as pathologists, surgeons, endocrinologists 
and clinical geneticists, assuring good quality of the work in different aspects. Other specialists in 
specific fields such as statisticians and bioinformaticians have also been consulted when needed. 
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